The invention relates to acid addition salts for the compounds of formula I or a pharmacologically of: Wherein R is hydrogen or lower alkyl R 1 is - (CH 2)n - (O) o -, and heterocycloalkyl, wherein the heterocycloalkyl groups are optionally, lower alkyl, hydroxy, halogen or - heterocycloalkyl or -C (O) (CH 2 ) p - is substituted with aryl n is 0, 1 or 2 o is 0 or 1 p is 0, 1 or 2 R 2 is CF 3 Optionally lower alkoxy- or halogen-substituted cycloalkyl 2-yl Optionally the heteroaryl-substituted heterocycloalkyl Or an aryl or heteroaryl, Wherein the aromatic ring is optionally, lower alkyl, halogen, heteroaryl, hydroxy, CF 3, OCF 3, OCH 2 CF 3, OCH 2 - cycloalkyl, OCH 2 C (CH 2 OH) (CH 2 Cl) (CH 3), S- lower alkyl, lower alkoxy, CH 2 - lower alkoxy, lower alkynyl, cyano, -C (O) - phenyl, -O- phenyl, -O-CH 2 - phenyl, phenyl and -CH 2 - which is substituted with 1 or 2 substituents selected from phenyl, wherein the phenyl ring is optionally, halogen, -C (O) - lower alkyl, -C (O) OH or -C (O) O- as a lower alkyl It may be substituted, Aromatic ring is optionally, heterocycloalkyl, OCH 2 - 3-yl, or optionally lower alkyl-substituted O- substituted tetrahydropyran-4-days X is a bond,-NR-,-CH 2 NH-,-CHR -, - (CHR) q-O-,-O-(CHR) q - or - (CH 2)2 - ego Y is a bond or -CH 2 - and R is hydrogen or lower alkyl R is hydrogen, lower alkyl, CF 3, lower alkoxy q is 0, 1, 2 or 3 The compounds of formula I were found to have excellent affinity for the trace amine associated receptors (TAAR), especially TAAR1. The compounds are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, energy consumpt
